Lilly ' s Donanemab receives U.S. FDA ' s Breakthrough Therapy Designation for Treatment of Alzheimer ' s disease

INDIANAPOLIS, June 24, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company ' s (NYSE: LLY) investigational antibody therapy for Alzheimer ' s...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials